Synthorx was a clinical-stage biopharmaceutical company focused on developing engineered proteins for cancer treatment using proprietary expanded genetic code technology. The San Diego-based company utilized a platform called THOR (Therapeutic Hypothesis-Oriented Research) to create novel protein therapeutics with enhanced properties compared to natural proteins.
Founded in 2014, Synthorx went public in 2019 but was later acquired by Sanofi in 2020 for approximately $2.5 billion, representing one of the largest biotech acquisitions of that year. The company's lead program involved engineered interleukin-2 (IL-2) therapies designed to activate the immune system against cancer while reducing toxicity. The acquisition by Sanofi highlighted the significant value and potential of Synthorx's protein engineering platform in advancing next-generation immunotherapies for oncology applications.
Synthorx has received investment from 1 venture capital firm.
Biopharmaceutical company developing engineered protein therapeutics for cancer using expanded genetic code technology.
Synthorx has received investment from AbbVie. These venture capital firms and investors provide both capital and strategic support.
Synthorx operates in the Biotech sector. Biopharmaceutical company developing engineered protein therapeutics for cancer using expanded genetic code technology.
